5.83
price up icon4.95%   0.275
 
loading
Schlusskurs vom Vortag:
$5.555
Offen:
$5.67
24-Stunden-Volumen:
3.80M
Relative Volume:
1.38
Marktkapitalisierung:
$518.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-2.67%
1M Leistung:
+14.09%
6M Leistung:
+62.40%
1J Leistung:
+161.43%
1-Tages-Spanne:
Value
$5.4587
$5.90
1-Wochen-Bereich:
Value
$5.15
$6.905
52-Wochen-Spanne:
Value
$1.67
$6.905

Atyr Pharma Inc Stock (ATYR) Company Profile

Name
Firmenname
Atyr Pharma Inc
Name
Telefon
(858) 731-8389
Name
Adresse
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Name
Mitarbeiter
59
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
ATYR's Discussions on Twitter

Vergleichen Sie ATYR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ATYR
Atyr Pharma Inc
5.83 494.42M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-18 Eingeleitet Leerink Partners Outperform
2025-01-06 Eingeleitet Cantor Fitzgerald Overweight
2024-10-04 Eingeleitet Wells Fargo Overweight
2024-09-05 Eingeleitet Jefferies Buy
2023-07-05 Herabstufung Oppenheimer Outperform → Perform
2021-10-12 Eingeleitet RBC Capital Mkts Outperform
2021-09-21 Eingeleitet Piper Sandler Overweight
2021-05-10 Eingeleitet Laidlaw Buy
2020-08-17 Hochstufung H.C. Wainwright Neutral → Buy
2020-03-04 Eingeleitet ROTH Capital Buy
2020-03-02 Eingeleitet Oppenheimer Outperform
2018-02-14 Herabstufung JP Morgan Neutral → Underweight
2017-09-07 Eingeleitet Piper Jaffray Overweight
2016-12-13 Herabstufung JP Morgan Overweight → Neutral
2015-12-16 Eingeleitet Citigroup Neutral
2015-06-01 Eingeleitet Citigroup Buy
2015-06-01 Eingeleitet JP Morgan Overweight
Alle ansehen

Atyr Pharma Inc Aktie (ATYR) Neueste Nachrichten

pulisher
Jul 25, 2025

Does aTyr Pharma Inc. stock pay reliable dividendsHigh-performance investment picks - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

RNA Therapeutics and Vaccines Market Industry Trends & Forecasts to 2035, with Profiles of Alphavax, Arcturus Therapeutics, aTyr Pharma, Gritstone Bio, HDT Bio, MiNA Therapeutics, & VLP TherapeuticsResearchAndMarkets.com - FinancialContent

Jul 25, 2025
pulisher
Jul 23, 2025

GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday - Benzinga

Jul 23, 2025
pulisher
Jul 23, 2025

aTyr Pharma Soars 11.26% on Phase 3 Study Completion - AInvest

Jul 23, 2025
pulisher
Jul 23, 2025

aTyr Pharma stock holds Buy rating as Phase 3 trial completes - Investing.com Canada

Jul 23, 2025
pulisher
Jul 23, 2025

Is aTyr Pharma Inc. a good long term investmentRecord-breaking gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

High-Risk, High-Reward Opportunity in aTyr Pharma’s Efzofitimod Amid Upcoming Phase 3 Readout - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about aTyr Pharma Inc. stockMarket-leading capital gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

aTyr Pharma Announces Last Patient Visit in Phase 3 - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

What drives aTyr Pharma Inc. stock priceMarket-beating returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

aTyr Pharma Inc. Stock Analysis and ForecastFree Risk Assessment Services - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

aTyr Pharma announces last patient visit in Phase 3 EFZO-FIT study - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

First-Ever Global Phase 3 Trial for Sarcoidosis Treatment Reaches Major Milestone with 268 Patients - Stock Titan

Jul 22, 2025
pulisher
Jul 19, 2025

aTyr Pharma Reaches US$515m Market Cap Benefiting Insider Stock Buying - simplywall.st

Jul 19, 2025
pulisher
Jul 18, 2025

aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Jul 18, 2025
pulisher
Jul 18, 2025

RNA Therapeutics and RNA Vaccines Market Industry Report 2025-2035: Investments in RNA Technologies Surge with USD 2.9 Billion Funding - GlobeNewswire Inc.

Jul 18, 2025
pulisher
Jul 16, 2025

What makes aTyr Pharma Inc. stock price move sharplyFree Stock Trading Community - beatles.ru

Jul 16, 2025
pulisher
Jul 15, 2025

How aTyr Pharma Inc. stock performs during market volatilityTop Growth Low Risk Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why aTyr Pharma Inc. stock attracts strong analyst attentionProven Win Setups - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Can ATyr's EFZO-FIT Data Help Patients And Investors Breathe Easier? - RTTNews

Jul 14, 2025
pulisher
Jul 11, 2025

Pulmonary Sarcoidosis Market on Track for Major Expansion - openPR.com

Jul 11, 2025
pulisher
Jul 11, 2025

Pulmonary Sarcoidosis Market on Track for Major Expansion by 2032, According to DelveInsight | aTyr Pharma, Kinevant Sciences, Novartis, aTyr Pharma, Novartis Pharma, Mallinckrodt - Barchart.com

Jul 11, 2025
pulisher
Jul 07, 2025

Favourable Signals For aTyr Pharma: Numerous Insiders Acquired Stock - Yahoo Finance

Jul 07, 2025
pulisher
Jul 06, 2025

Super League Enterprise And 2 Other Stocks Under $2 Insiders Are Buying - MSN

Jul 06, 2025
pulisher
Jun 30, 2025

ATyr Pharma, Inc.(NasdaqCM: ATYR) added to Russell Small Cap Comp Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 29, 2025

ATyr Pharma, Inc.(NasdaqCM: ATYR) added to Russell 3000E Value Index - MarketScreener

Jun 29, 2025
pulisher
Jun 27, 2025

Leerink Partners Sticks to Its Buy Rating for aTyr Pharma (ATYR) - The Globe and Mail

Jun 27, 2025
pulisher
Jun 26, 2025

aTyr Pharma to join Russell 2000 and 3000 indexes By Investing.com - Investing.com India

Jun 26, 2025

Finanzdaten der Atyr Pharma Inc-Aktie (ATYR)

Es liegen keine Finanzdaten für Atyr Pharma Inc (ATYR) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Kapitalisierung:     |  Volumen (24h):